HBOT Conversations:
Tom Fox (Part 1)
Tom is the Research Physiologist for the Hyperbaric Institute for Research and Training, a division of Island Hyperbaric Centre in Pincourt QC. He has worked in the field of Clinical Hyperbaric Oxygen for the last 30 years, and has been intimately involved with the implementation and the development of the US Army’s Clinical Hyperbaric Service at Dwight David Eisenhower Army Medical Center. Tom is a senior army aviator and flew twelve years as a Medical Evacuation Pilot for the US Army.
Tom joined the Extivita-RTP team in 2022 as the Safety Director, and is joining us in a 2-part series to discuss the history of Hyperbaric Oxygen Therapy and dive into his personal experience healing patients with HBOT.
Watch the Podcast
We appreciate HBOT historian, Tom Fox, returning to HBOT News to dive in deeper to the history of Hyperbarics, which we can date back to the 1660s!
Tom explains that in the 1830s, the first clinical use of hyperbarics was used and introduced, this revived Nathaniel Henshaw’s concept of Hyperbaric treatments. Nathaniel Henshaw, a clergyman, built a sealed chamber in 1662. Henshaw believed that the application of higher pressure (hyperbaria) was good to treat acute conditions, and that lower pressure (hypobaria) would be better to treat chronic diseases.

1662, Henshaw’s “Domicilium” hyperbaric chamber
This is an interesting fact, because now we’re learning that the cyclic use of hyperbaria (or relative hyperbaria) and hypobaria is very intriguing in what it’s doing from the standpoint of physiology. Tom mentions Dr. Efrati and his group of researchers have been at the forefront of looking at this, and are doing a phenominal job of conducting the hyperbaric studies and getting the hyperbaric education out there. There’s been very limited commitment to do this, he commends Dr. Efrati and his group at Tel Aviv for all they do for the HBOT industry. What you will witness throughout the history of hyperbarics is that they’ve used slightly pressurized room air, and that’s important to know because the slightly pressurized room air has consistently been assumed not to have any effect. It’s even offered up as a control in many of the studies, like the placebo. But the problem is when the placebo helps and the treatment helps, it’s easy to say that the reason both groups are getting better is because of the “participation effect”, or it being “in their heads”. And Dr. Efrati is bringing all this to light. This information is also changing the way the HBOT industry looks at the application of air breaks within the protocols. The use of air breaks was thought to fight oxygen toxicity, but now it’s used to establish a relative hypoxia without going into hypoxic conditions. Host di Girolamo then breaks all of that information down for the viewer to better understand…
So to paraphrase that, you’re breathing pure oxygen and also now you’re breathing air, your body says, ‘oh, oxygen’s depleting, you’re suffocating.’ All these mechanisms occur in your physiology, and then the body’s like, ‘Oh, no, everything’s okay. We have plenty of oxygen.’ So that five minute air break triggers that, and then he’s doing it, I think, three or four times in a 90 minute treatment and it ends up being therapeutic.
Continuing down the timeline of HBOT and fascinating discoveries in the 1800s, Tom Fox brings up a series of articles, Lectures on The Compressed Air Bath and its uses in the treatment of disease, that appeared in the British Medical Journal, dated April 18th, 1885 by a doctor, Theodore Williams. Tom reads the first paragraph from the first article:
“The use of atmospheric air under different degrees of barometric pressure in the treatment of disease is one of the most important advances in modern medicine. When we consider the simplicity of the agent, the exact method by which it is applied, and the precision with which it can be regulated to the requirements of each individual, we are astonished that in England, this method of treatment has been so little used.” – Theodore Williams
That was almost 150 years ago. Back then they were just taking air and putting you under pressure. Now it’s a breakthrough medical treatment, and it’s still not being used in the manner that it could/should be. Almost 200 years ago we were on the cutting edge of medicine! And today we still have to fight to explain that even slightly pressurized room air has a therapeutic benefit — using pressure for healing purposes has literally been happening since the 1600s.

Apparently, Cunningham had some difficulty justifying it all by scientific standards, and this was a very new concept in US medicine. The world had never seen anything like it! Unfortunately, Cunningham fell victim toa unusual amount of scrutiny, and was eventually shut down with the chamber being sold for scrap metal during World War II.
So many people now see the value in Cunningham’s efforts and what he contributed to the HBOT industry. Finally, his work can be interpreted as vindication of the God-given miracle of oxygen and pressure to heal our bodies and minds.
Guests

Thomas M. Fox, MAS,MS, CHT - Safety Director at Extivita RTP & Research Physiologist for the Hyperbaric Institute for Research and Training
Tom is the Research Physiologist for the Hyperbaric Institute for Research and Training, a division of Island Hyperbaric Centre in Pincourt QC. He has worked in the field of Clinical Hyperbaric Oxygen for the last 30 years. During this time, he has been intimately involved with the implementation and the development of the US Army’s Clinical Hyperbaric Service at Dwight David Eisenhower Army Medical Center. He has provided contract hyperbaric services since 1997. Prior to accepting his current position in Quebec, Canada, Mr. Fox served as the Chief of the Atmospherics Branch of the U.S. Army School of Aviation Medicine, Fort Rucker Alabama. In this capacity, he was responsible for hyperbaric/ hypobaric operations and training of US and NATO aviators, flight surgeons and flight medics. Mr. Fox is a senior army aviator and flew twelve years as a Medical Evacuation Pilot for the US Army.
Tom joined the Extivita team in 2022 as the Safety Director, helping Extivita to maintain a healthy and safe environment for exceptional patient care.
Subscribe Now, It’s Free!
Recent HBOT News
Healing of spongiosus-cutaneous fistula with Hyperbaric Oxygen Therapy (HBOT): a case report.
Abstract: We present a case of a spongiosus-cutaneous fistula in a 39-year-old man with recurrent episodes of cutaneous abscess in dorsal middle third penis (5 - 3 cm) treated with Hyperbaric Oxygen Therapy (HBOT). After emptying nodular abscess, the patient was...
Clinical Trial – Caudal Block,Saddle Block, Anorectal Surgery
Anorectal surgery includes pilonidal sinus, hemorrhoidectomy, anal fissure, and anal fistula
operations. Various surgical and anesthetic techniques have been used to increase the level
of analgesia in perioperative period and decrease the length of stay in the hospital. In this
study, investigators investigate the effects of routinely applied anesthesia techniques
during anorectal surgery, caudal block and saddle block, on patients’ perioperative
hemodynamic values, sensory and motor block levels, and postoperative pain scores.
Clinical Trial – Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with recurrent
mucosal inflammation. Clinically, the disease is characterized by bloody diarrhea, abdominal
pain, and constitutional symptoms such as fever and weight loss. Treatment strategies vary
based on disease activity and target various aspects of the inflammatory cascade. Options
include: anti-inflammatory drugs (mesalamine), immunosuppressive or modulatory medications
(corticosteroids, thiopurines, cyclosporine) and biologic agents (Anti-TNF). Disease severity
can be wide ranging, and nearly 25% of UC patients are hospitalized for acute severe disease.
Of these patients, 30% will undergo colectomy after the acute episode, a quarter of which
will experience post-operative complications. Although there has been great progress in
treatment of UC over the past decade, even with the anti-TNF agent infliximab, the one-year
remission rate for patients not responding to conservative management is barely 20%.
Furthermore, corticosteroids have significant long-term consequences and immune suppressive
drugs such as 6-mercaptopurine, azathioprine and infliximab have been associated with serious
adverse events including life-threatening infections and lymphomas. With growing evidence
that the pathogenesis of UC is multi-factorial and involves a complex interaction of genetic
and environmental factors, newer treatment modalities are being evaluated to target the
mucosal immune response and mucosal inflammatory regulatory system.
Hyperbaric oxygen offers a promising new treatment option since it targets both tissue
hypoxia and inflammation. Recent small scales studies evaluating the impact of hyperbaric
oxygen treatment in acute ulcerative colitis flares demonstrated improved outcomes. The
mechanisms underlying the improvement are not known. In this study, we will treat ulcerative
colitis flares with hyperbaric oxygen and measure changes in both markers of tissue hypoxia
and inflammation. We hypothesize that hyperbaric oxygen will (a) improve outcomes, and (b)
show reductions in markers of both tissue hypoxia and inflammation.
